The Impact of Atrial Fibrillation on Quality of Life and Healthcare Costs

By Melike Belenli Gümüş

September 26, 2024

Introduction

The impact of atrial fibrillation (AF), as the most common cardiac arrhythmia, is substantial, affecting 60 million people globally, including 14 million in Europe. This condition significantly increases the risk of severe health issues. AF patients face a five-fold increase in stroke risk, a three-fold increase in heart failure (HF) risk, and a two-fold increase in myocardial infarction (MI) risk. Approximately 75% of AF patients experience clinical symptoms, contributing to an annual management cost in Europe ranging from €450 to €3000, depending on co-morbidities.

Recent advancements in AF treatment, such as non-vitamin K antagonist oral anticoagulants and more effective ablation techniques, have potentially improved patient quality of life (QoL) and reduced healthcare costs. However, previous studies may not reflect the current clinical landscape due to changes in guideline recommendations emphasising stroke prevention and symptom management.

With an ageing population, improved diagnostic methods, and increasing cardiovascular risk factors like hypertension and obesity, AF prevalence is expected to rise. Despite this, a comprehensive assessment of the association between AF symptoms, cardiovascular disease (CVD) events, health-related quality of life (HRQOL), healthcare resource use, healthcare costs, and patient outcomes is lacking. Understanding these dynamics is crucial for improving patient care and managing healthcare expenses effectively.

Patient Characteristics and Study Design

To address this issue, a recent study analysed data from a patient population across 27 countries in Europe and Central Asia. The study enrolled patients from 250 centres, following them for two years. The average age was 70 years, with 40% being female. Patients were classified based on the European Heart Rhythm Association (EHRA) symptom score, with 36% experiencing mild symptoms and 19% severe or disabling symptoms.

The primary outcomes were HRQOL and healthcare costs. Secondary outcomes included the number of emergency room (ER) admissions, cardiology visits, and general practitioner (GP) visits. HRQOL was measured using the EQ-5D-5L questionnaire, which assesses mobility, self-care, usual activities, pain or discomfort, and anxiety or depression.

Impact of AF on HRQOL

The study revealed that AF symptoms and CVD events significantly decrease HRQOL. Severe symptoms and events like ST-segment elevation myocardial infarction (STEMI), thromboembolic incidents, and worsening HF were linked to notable HRQOL reductions. These findings align with earlier studies that reported negative associations between symptom severity and HRQOL. For example, the Swiss-AF study found severe symptoms led to a 0.069 reduction in EQ-5D scores.

Impact of AF on Healthcare Costs

CVD events and, to a lesser extent, symptoms were associated with increased healthcare costs, primarily driven by inpatient care. The study found that severe or disabling symptoms increased healthcare costs by €544, while mild symptoms had a marginal effect. Cardiovascular events had a substantial impact on costs, with angina/non-STEMI (NSTEMI) adding €5823, STEMI €11,718, new-onset/worsening HF €3689, thromboembolic events €3182, and bleeding events €3792 annually. These findings highlight the significant financial burden of cardiovascular events on healthcare systems.

Previous studies also highlighted significant cost contributions from coronary artery disease, cerebrovascular disease, and HF. For instance, a Danish study reported an average total cost of €49,576 over three years for ischaemic stroke patients with AF.

Figure 1. Marginal effects of symptoms and CVD events on (A) HRQOL and (B) healthcare costs (€) by region.

Regional and Gender Differences

There were no significant differences in HRQOL or healthcare costs between European regions (Figure 1) or by sex. This finding contrasts with some studies suggesting higher care home costs for women. However, the study did not include care home costs, and further research is needed to confirm these results.

Conclusion

Cardiovascular events and severe symptoms in AF patients lead to increased healthcare costs and reduced QoL. Effective management strategies are essential to mitigate these impacts and improve patient outcomes. These findings highlight the need for continued innovation in AF management to improve patient outcomes and reduce healthcare costs. Furthermore, by understanding the cost drivers and patient needs, healthcare providers can better allocate resources and enhance care delivery.

Reference url

Recent Posts

early aortic stenosis surgery
        

Earlier Surgery Recommended for Heart-Valve Patients: New Study Insights

💔 Are we waiting too long for heart health interventions?

A recent study suggests that patients with severe aortic stenosis may benefit significantly from earlier surgical intervention, overturning traditional ‘wait and see’ practices. This shift, utilizing minimally invasive techniques, could prove vital in reducing unexpected hospitalizations and improving overall outcomes for patients, especially seniors. Learn more about this pivotal research that may redefine treatment protocols in cardiology!

#SyenzaNews #HealthcareInnovation #ClinicalTrials #MedTech #HealthTech

cross-border health surveillance
   

Strengthening Cross-Border Health Surveillance in Africa

🌍 How can enhanced cross-border surveillance improve public health security in Africa?

Check out the Africa CDC’s newly launched Strategic Framework that aims to bolster collaboration and information sharing among African Union Member States. This initiative tackles the challenges of health threats linked to population movement by promoting robust systems for surveillance and response. Discover how these efforts can pave the way for safer communities across the continent!

#SyenzaNews #globalhealth #HealthcareInnovation #DigitalTransformation #HealthTech

regional immunization framework
              

Strengthening Immunisation in the Eastern Mediterranean: WHO Launches Regional Framework

🌍 How can strengthening immunisation in the Eastern Mediterranean transform public health?

The recent launch of the regional framework by WHO is a crucial step towards enhancing vaccine access and addressing disparities in coverage. This initiative, inaugurated in Doha, aims to save millions of lives by ensuring everyone has access to essential vaccines, especially in conflict-affected areas. Discover how this framework can pave the way for healthier communities!

#SyenzaNews #GlobalHealth #HealthForAll #HealthcareInnovation #Immunisation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.